Mycophenolate mofetil in lupus glomerulonephritis: Effectiveness and tolerability

Luca Iaccarino, Silvia Arienti, Mariaelisa Rampudda, Mariagrazia Canova, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Andrea Doria

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Mycophenolate mofetil (MMF) is an immunosuppressive agent initially used in the treatment of transplant recipients. MMF has been used in renal, heart, and liver transplantation, where it seems more effective than other immunosuppressive regimens in reducing the incidence of acute rejection episodes. MMF has a variety of immunosuppressive effects, including selective suppression of T and B lymphocyte proliferation, and has been more recently used in many autoimmune inflammatory conditions. Systemic lupus erythematosus (SLE) is an autoimmune disease that can potentially involve any organ or system of the human body. Glomerulonephritis (GLN) has been recognized as the most frequent severe manifestation of SLE, leading to poor long-term prognosis. In the treatment of lupus GLN, several therapeutic approaches, all including immunosuppressive drugs, such as cyclophosphamide, azathioprine, or cyclosporine A, have been used. The short- and long-term toxicity of these drugs limits their use in a substantial number of patients. Over the last few years, MMF has emerged as an alternative therapeutic regimen in lupus GLN, mainly for patients refractory to other therapies. These studies have shown that it is highly effective and generally well tolerated.

Original languageEnglish
Title of host publicationAnnals of the New York Academy of Sciences
Pages516-524
Number of pages9
Volume1110
DOIs
Publication statusPublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1110
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Mycophenolic Acid
Lupus Nephritis
Immunosuppressive Agents
Systemic Lupus Erythematosus
Transplants
Lymphocytes
Azathioprine
Therapeutics
Pharmaceutical Preparations
Liver
Refractory materials
Cyclophosphamide
Cyclosporine
Toxicity
Heart Transplantation
Glomerulonephritis
Drug-Related Side Effects and Adverse Reactions
Human Body
Liver Transplantation
Kidney Transplantation

Keywords

  • Immunosuppressants
  • Lupus nephritis
  • Mycophenolate mofetil
  • Prognosis
  • Secondary prevention
  • Systemic lupus erythematosus
  • Therapy

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Iaccarino, L., Arienti, S., Rampudda, M., Canova, M., Atzeni, F., Sarzi-Puttini, P., & Doria, A. (2007). Mycophenolate mofetil in lupus glomerulonephritis: Effectiveness and tolerability. In Annals of the New York Academy of Sciences (Vol. 1110, pp. 516-524). (Annals of the New York Academy of Sciences; Vol. 1110). https://doi.org/10.1196/annals.1423.055

Mycophenolate mofetil in lupus glomerulonephritis : Effectiveness and tolerability. / Iaccarino, Luca; Arienti, Silvia; Rampudda, Mariaelisa; Canova, Mariagrazia; Atzeni, Fabiola; Sarzi-Puttini, Piercarlo; Doria, Andrea.

Annals of the New York Academy of Sciences. Vol. 1110 2007. p. 516-524 (Annals of the New York Academy of Sciences; Vol. 1110).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Iaccarino, L, Arienti, S, Rampudda, M, Canova, M, Atzeni, F, Sarzi-Puttini, P & Doria, A 2007, Mycophenolate mofetil in lupus glomerulonephritis: Effectiveness and tolerability. in Annals of the New York Academy of Sciences. vol. 1110, Annals of the New York Academy of Sciences, vol. 1110, pp. 516-524. https://doi.org/10.1196/annals.1423.055
Iaccarino L, Arienti S, Rampudda M, Canova M, Atzeni F, Sarzi-Puttini P et al. Mycophenolate mofetil in lupus glomerulonephritis: Effectiveness and tolerability. In Annals of the New York Academy of Sciences. Vol. 1110. 2007. p. 516-524. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1423.055
Iaccarino, Luca ; Arienti, Silvia ; Rampudda, Mariaelisa ; Canova, Mariagrazia ; Atzeni, Fabiola ; Sarzi-Puttini, Piercarlo ; Doria, Andrea. / Mycophenolate mofetil in lupus glomerulonephritis : Effectiveness and tolerability. Annals of the New York Academy of Sciences. Vol. 1110 2007. pp. 516-524 (Annals of the New York Academy of Sciences).
@inproceedings{da31cfd0252040c4a233326a6fa30f4b,
title = "Mycophenolate mofetil in lupus glomerulonephritis: Effectiveness and tolerability",
abstract = "Mycophenolate mofetil (MMF) is an immunosuppressive agent initially used in the treatment of transplant recipients. MMF has been used in renal, heart, and liver transplantation, where it seems more effective than other immunosuppressive regimens in reducing the incidence of acute rejection episodes. MMF has a variety of immunosuppressive effects, including selective suppression of T and B lymphocyte proliferation, and has been more recently used in many autoimmune inflammatory conditions. Systemic lupus erythematosus (SLE) is an autoimmune disease that can potentially involve any organ or system of the human body. Glomerulonephritis (GLN) has been recognized as the most frequent severe manifestation of SLE, leading to poor long-term prognosis. In the treatment of lupus GLN, several therapeutic approaches, all including immunosuppressive drugs, such as cyclophosphamide, azathioprine, or cyclosporine A, have been used. The short- and long-term toxicity of these drugs limits their use in a substantial number of patients. Over the last few years, MMF has emerged as an alternative therapeutic regimen in lupus GLN, mainly for patients refractory to other therapies. These studies have shown that it is highly effective and generally well tolerated.",
keywords = "Immunosuppressants, Lupus nephritis, Mycophenolate mofetil, Prognosis, Secondary prevention, Systemic lupus erythematosus, Therapy",
author = "Luca Iaccarino and Silvia Arienti and Mariaelisa Rampudda and Mariagrazia Canova and Fabiola Atzeni and Piercarlo Sarzi-Puttini and Andrea Doria",
year = "2007",
month = "9",
doi = "10.1196/annals.1423.055",
language = "English",
isbn = "1573317098",
volume = "1110",
series = "Annals of the New York Academy of Sciences",
pages = "516--524",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Mycophenolate mofetil in lupus glomerulonephritis

T2 - Effectiveness and tolerability

AU - Iaccarino, Luca

AU - Arienti, Silvia

AU - Rampudda, Mariaelisa

AU - Canova, Mariagrazia

AU - Atzeni, Fabiola

AU - Sarzi-Puttini, Piercarlo

AU - Doria, Andrea

PY - 2007/9

Y1 - 2007/9

N2 - Mycophenolate mofetil (MMF) is an immunosuppressive agent initially used in the treatment of transplant recipients. MMF has been used in renal, heart, and liver transplantation, where it seems more effective than other immunosuppressive regimens in reducing the incidence of acute rejection episodes. MMF has a variety of immunosuppressive effects, including selective suppression of T and B lymphocyte proliferation, and has been more recently used in many autoimmune inflammatory conditions. Systemic lupus erythematosus (SLE) is an autoimmune disease that can potentially involve any organ or system of the human body. Glomerulonephritis (GLN) has been recognized as the most frequent severe manifestation of SLE, leading to poor long-term prognosis. In the treatment of lupus GLN, several therapeutic approaches, all including immunosuppressive drugs, such as cyclophosphamide, azathioprine, or cyclosporine A, have been used. The short- and long-term toxicity of these drugs limits their use in a substantial number of patients. Over the last few years, MMF has emerged as an alternative therapeutic regimen in lupus GLN, mainly for patients refractory to other therapies. These studies have shown that it is highly effective and generally well tolerated.

AB - Mycophenolate mofetil (MMF) is an immunosuppressive agent initially used in the treatment of transplant recipients. MMF has been used in renal, heart, and liver transplantation, where it seems more effective than other immunosuppressive regimens in reducing the incidence of acute rejection episodes. MMF has a variety of immunosuppressive effects, including selective suppression of T and B lymphocyte proliferation, and has been more recently used in many autoimmune inflammatory conditions. Systemic lupus erythematosus (SLE) is an autoimmune disease that can potentially involve any organ or system of the human body. Glomerulonephritis (GLN) has been recognized as the most frequent severe manifestation of SLE, leading to poor long-term prognosis. In the treatment of lupus GLN, several therapeutic approaches, all including immunosuppressive drugs, such as cyclophosphamide, azathioprine, or cyclosporine A, have been used. The short- and long-term toxicity of these drugs limits their use in a substantial number of patients. Over the last few years, MMF has emerged as an alternative therapeutic regimen in lupus GLN, mainly for patients refractory to other therapies. These studies have shown that it is highly effective and generally well tolerated.

KW - Immunosuppressants

KW - Lupus nephritis

KW - Mycophenolate mofetil

KW - Prognosis

KW - Secondary prevention

KW - Systemic lupus erythematosus

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=35748969116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35748969116&partnerID=8YFLogxK

U2 - 10.1196/annals.1423.055

DO - 10.1196/annals.1423.055

M3 - Conference contribution

C2 - 17911467

AN - SCOPUS:35748969116

SN - 1573317098

SN - 9781573317092

VL - 1110

T3 - Annals of the New York Academy of Sciences

SP - 516

EP - 524

BT - Annals of the New York Academy of Sciences

ER -